期刊文献+

人表皮生长因子受体2阳性晚期胃癌分子靶向治疗的中国专家共识 被引量:9

原文传递
导出
摘要 胃癌是我国常见的消化道恶性肿瘤。2004--2008年,我国胃癌的年龄标化发病率无显著变化,但因人口结构老龄化加剧,胃癌的实际发病率稳中趋升,每年新发病例数仍位居世界前列”[1-4]。晚期胃癌患者预后不佳,胃癌死亡率列我国恶性肿瘤相关死亡第3位,总体5年生存率为30%~57.1%[5]。目前,我国胃癌早期筛查机制尚不完善,
作者 张俊
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2013年第4期315-319,共5页 Chinese Journal of Oncology
关键词 胃肿瘤 人表皮生长因子受体2 靶向治疗 曲妥珠单抗 专家共识 Stomach neoplasms Human epidermal growth factor receptor-2 Targeted therapy Trastuzumab Expert consensus
  • 相关文献

参考文献34

  • 1Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol, 2009, 472:467-477.
  • 2Zhao P, Dai M, Chen W, et al. Cancer trends in China. Jpn J Clin Oncol, 2010, 40:281-285.
  • 3张思维,陈万青,雷正龙,邹小农,赵平.中国肿瘤登记处2004年恶性肿瘤发病资料分析[J].中国肿瘤,2008,17(11):909-912. 被引量:78
  • 4郑荣寿,张思维,吴良有,李光琳,赵平,赫捷,陈万青.中国肿瘤登记地区2008年恶性肿瘤发病和死亡分析[J].中国肿瘤,2012,21(1):1-12. 被引量:561
  • 5Li ZX, Kaminishi M. A comparison of gastric cancer between Japan and China. Gastric Cancer, 2009, 12:52-53.
  • 6Wu AW, Ji JF, Yang H, et al. Long-term outcome of a large series of gastric cancer patients in China. Chin J Cancer Res, 2010, 22 : 167-175.
  • 7王喜,吴春晓,郑莹,王杰军.上海市区胃癌发病的时间趋势和特点分析[J].中华流行病学杂志,2007,28(9):875-880. 被引量:29
  • 8Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 2008, 358 : 36-46.
  • 9Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer. ( ToGA ) : a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376:687-697.
  • 10Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun, 2004, 319 : 1-11.

二级参考文献128

  • 1张思维,雷正龙,李光琳,邹小农,陈万青,赵平.中国肿瘤登记地区2005年发病死亡资料分析[J].中国肿瘤,2009,18(12):973-979. 被引量:32
  • 2KatherineDCrew,AlfredINeugut.Epidemiology of gastric cancer[J].World Journal of Gastroenterology,2006,12(3):354-362. 被引量:191
  • 3Ling Yang.Incidence and mortality of gastric cancer in China[J].World Journal of Gastroenterology,2006,12(1):17-20. 被引量:345
  • 4Jensen OM, Parkin DM, Maclennan R, et al. Cancer registration: principles and methods. IARC scientific publication No. 95[M]. Lyon: IARC, 1991.
  • 5Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IARC technical report No.19[M]. Lyon: IARC, 1994.
  • 6Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC technical report No.42[M]. Lyon: IARC, 2005.
  • 7Felay J. The IARCcrgTools program[DB/OL], http://www.iacr.com.fr/iarccrgtools.htm. 2006.
  • 8陈竺.全国第三次死因回顾抽样调查报告[M].北京:中国协和医科大学出版社,2008:11-12.
  • 9Albanell J, Montagut C, Jones ET, Pronk L, Mel- lado B, Beech J, Gascon P, Zugmaier G, Brewster M, Saunders MP, Valle JW. A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in pa- tients with advanced solid tumors. Clin Cancer Res 2008; 14:2726-2731.
  • 10Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28:1138-1144.

共引文献800

同被引文献118

引证文献9

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部